Atlas Trials

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Clinical trial NCT02875067 · TERMINATED

Trial details

NCT number
NCT02875067
Sponsor
NYU Langone Health
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma
Start date
2016-08-29
Primary completion
2017-10-02
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.